Patents Assigned to Bristol-Myers Squibb Company
-
Publication number: 20250145712Abstract: This disclosure provides methods for treating a subject afflicted with a tumor derived from a renal cell carcinoma. The methods comprise administering a first dose to a subject of an anti-PD-1 antibody or antigen-binding portion thereof and/or an anti-PD-L1 antibody or antigen-binding portion thereof, and administering a second dose to the subject, wherein the subject exhibited differential expression in one or more biomarker genes, e.g., CTLA-4, TIGIT, and/or PD-L2, following administration of the first dose.Type: ApplicationFiled: October 15, 2024Publication date: May 8, 2025Applicant: Bristol-Myers Squibb CompanyInventors: Jason Samuel SIMON, Petra B. ROSS-MACDONALD
-
Publication number: 20250145713Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: ApplicationFiled: January 9, 2025Publication date: May 8, 2025Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
-
Patent number: 12291517Abstract: Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.Type: GrantFiled: January 29, 2023Date of Patent: May 6, 2025Assignee: Bristol-Myers Squibb CompanyInventor: Daniel Richard Roberts
-
Patent number: 12291522Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.Type: GrantFiled: May 27, 2021Date of Patent: May 6, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Chunjian Liu, Wei Wang, Bruce A. Ellsworth, James Aaron Balog, Alicia Regueiro-Ren
-
Publication number: 20250136988Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: November 7, 2024Publication date: May 1, 2025Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/SInventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, JR., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. MCDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
-
Publication number: 20250136684Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.Type: ApplicationFiled: November 22, 2024Publication date: May 1, 2025Applicant: Bristol-Myers Squibb CompanyInventors: Nils LONBERG, Mohan SRINIVASAN
-
Publication number: 20250134996Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment for Hodgkin lymphoma.Type: ApplicationFiled: October 2, 2024Publication date: May 1, 2025Applicant: Bristol-Myers Squibb CompanyInventor: Benedetto FARSACI
-
Publication number: 20250139123Abstract: A method includes receiving a request to reconcile a first set of data stored in a first datastore and a second set of data stored in a second datastore, retrieving, from the first datastore, the first set of data, and retrieving, from the second datastore, the second set of data. The first set of data includes one or more first rows each including a respective first data value and the second set of data includes one or more second rows each including a respective second data value. The method also includes determining a mismatch between a respective one of the first data values and a respective one of the second data values. Based on determining the mismatch, the method also includes updating the respective one of the second data values to match the respective one of the first data values.Type: ApplicationFiled: January 3, 2025Publication date: May 1, 2025Applicant: Bristol-Myers Squibb CompanyInventors: Sahith Doppalapudi, Sumit Nagpal
-
Patent number: 12286428Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X1 and X2 are independently C or N, provided that zero or one of X1 and X2 is N; Ring A represented by the structure is: or; and Q, R1, R2, R3, R4, R6, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.Type: GrantFiled: July 16, 2020Date of Patent: April 29, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Satheesh Kesavan Nair, Venkatram Reddy Paidi, Kandhasamy Sarkunam, Ramesh Kumar Sistla, John Hynes, Natesan Murugesan
-
Patent number: 12286424Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.Type: GrantFiled: May 10, 2021Date of Patent: April 29, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Prasada Rao Jalagam, Susheel Jethanand Nara, Manoranjan Panda, Murugesan Natesan, Pratik Devasthale
-
Publication number: 20250129061Abstract: Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins, and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.Type: ApplicationFiled: December 4, 2024Publication date: April 24, 2025Applicant: Bristol-Myers Squibb CompanyInventors: Lan-Ying QIN, Zheming RUAN, Ashok Vinayak PURANDARE, Emily Charlotte CHERNEY, James Aaron BALOG, Arvind MATHUR, Samuel J. BONACORSI
-
Publication number: 20250129166Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: November 7, 2024Publication date: April 24, 2025Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
-
Patent number: 12281108Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.Type: GrantFiled: November 25, 2019Date of Patent: April 22, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Nicholas R. Wurtz, James A. Johnson, Zulan Pi, Andrew Quoc Viet
-
Patent number: 12281085Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; in combination with an additional cancer therapeutic agent, and methods of use thereof for treating diseases and disorders such as cancer.Type: GrantFiled: October 22, 2020Date of Patent: April 22, 2025Assignees: Immunome, Inc., Bristol-Myers Squibb CompanyInventors: Matti Davis, Bruce S. Fischer, Gaurav Bajaj
-
Patent number: 12282492Abstract: Provided herein are system, apparatus, device, method and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for generating an output indicating differences in the data stored in disparate data storage devices and/or for reconciling data stored in disparate data storage devices. In an embodiment, a server loads a first subset of a first set of data corresponding to one or more first columns and a second subset of a second set of data corresponding to one or more second columns into a data repository. The server identifies one or more differences between the first subset of data and the second subset of data in the data repository, and causes display of the one or more differences. The server may generate an output including the first and second sets of data, and a visual indicator indicating each of the one or more differences and causes display of the output.Type: GrantFiled: June 24, 2022Date of Patent: April 22, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Sahith Doppalapudi, Sumit Nagpal
-
Patent number: 12275721Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.Type: GrantFiled: October 2, 2020Date of Patent: April 15, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Jie Chen, Carolyn Diane Dzierba, Junqing Guo, Amy C. Hart, William J. Pitts, Sing-Yuen Sit
-
Patent number: 12275720Abstract: The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.Type: GrantFiled: May 4, 2021Date of Patent: April 15, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Susheel Jethanand Nara, Manoranjan Panda, Pratik Devasthale, Alicia Regueiro-Ren
-
Patent number: 12275719Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.Type: GrantFiled: March 25, 2020Date of Patent: April 15, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Chunjian Liu, David S. Yoon, Wei Wang, Jianxin Feng, Bruce A. Ellsworth, Alicia Regueiro-Ren
-
Patent number: 12275718Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.Type: GrantFiled: December 4, 2019Date of Patent: April 15, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Jacob Swidorski, Brett R. Beno, David S. Yoon, Alicia Regueiro-Ren
-
Publication number: 20250115664Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.Type: ApplicationFiled: September 20, 2024Publication date: April 10, 2025Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG